Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1230-1238

  Butsch, Raphael ^a,b   Lukas Waelti, Stephan ^a   Schaerer, Sarah ^a   Braun, Julia ^c   Korol, Dimitri ^c   Probst Hensch, Nicole ^d,e   Moch, Holger ^a   Kurrer, Michael ^a,f  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Kantonsspital Muensterlingen   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f Pathologie Institut Enge   (Switzerland)

Author keywords

Follicular lymphoma; interferon ; microenvironment; plasmacytoid dendritic cells; tumor stroma

Indexed keywords

ALPHA INTERFERON; CD3 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL FUNCTION; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLASMA CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; DENDRITIC CELLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; T-LYMPHOCYTES;

EID: 79959588897     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.569619     Document Type: Article

References (49)

1. A clinical evaluation of the International Lymphoma Study Group classification of Non-Hodgkin's Lymphoma. The Non- Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-3918.
2. Hiddemann W, Buske C, Dreyling M, et al. Current management of follicular lymphomas. Br J Haematol 2007; 136:191-202. (Pubitemid 46020746)
3. Luminari S, Federico M. Prognosis of follicular lymphomas. Hematol Oncol 2006;24:64-72. (Pubitemid 44023094)
4. Armitage JO, Cavalli F, Longo DL. Text atlas of lymphomas. London: Martin Dunitz; 1999.
5. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426-2433. (Pubitemid 47007616)
6. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells. N Engl J Med 2004;351:2159-2169. (Pubitemid 39507628)
7. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104: 1258-1265. (Pubitemid 39166497)
8. Gine E, Montoto S, Bosch F, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006;17:1539-1545. (Pubitemid 44542041)
9. Cogliatti SB, Schmid U. Who is WHO and what was REAL? Swiss Med Wkly 2002;132:607-617.
10. Koster A, Tromp HA, Raemaekers JM, et al. The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 2007;92:184-190.
11. Kuppers R. Prognosis in follicular lymphoma-it's in the microenvironment. N Engl J Med 2004;351:2152-2153.
12. De Jong D. Molecular pathogenesis of follicular lymphoma:a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358-6363. (Pubitemid 46218847)
13. Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105: 301-307. (Pubitemid 40053097)
14. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-398. (Pubitemid 350002987)
15. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-2174. (Pubitemid 41291735)
16. Alvaro T, Lejeune M, Camacho FI, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006;91:1605-1612. (Pubitemid 46032957)
17. Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350-5357. (Pubitemid 46623165)
18. Wahlin BE, Sander B, Christensson B, et al. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388-397. (Pubitemid 46225341)
19. Koster A, van Krieken JH, Mackenzie MA, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005;11:154-161. (Pubitemid 40075790)
20. Farinha P, Kyle A, Minchinton A, et al. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010;95:2157-2160.
21. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
22. Kadowaki N. The divergence and interplay between pDC and mDC in humans. Front Biosci 2009;14:808-817.
23. Gascoyne RD, Rosenwald A, Poppema S, et al. Prognostic biomarkers in malignant lymphomas. Leuk Lymphoma 2010;51(Suppl. 1):11-19.
24. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-1837.
25. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
26. Kadowaki N, Antonenko S, Lau JY, et al. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000;192:219-226.
27. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215-2223. (Pubitemid 46218713)
28. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949. (Pubitemid 32012762)
29. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968-974. (Pubitemid 35215839)
30. Roche PC, Hsi ED. Immunohistochemistry - principles and advances. In: Rose NR, Hamilton RG, Detrick B, editors. Manual of clinical laboratory immunology. 6th ed. Washington, DC: American Society for Microbiology Press; 2002. pp. 380-386.
31. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580. (Pubitemid 11147380)
32. Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 1997;94:12551-12556. (Pubitemid 27492566)
33. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
34. Cox DR. Regression models and life tables. J R Stat Assoc 1972;34:187-220.
35. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003;63:6478-6487. (Pubitemid 37255200)
36. Nestle FO, Burg G, Fah J, et al. Human sunlightinduced basal-cell-carcinoma-associated dendritic cells are deficient in T-cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997; 150:641-651. (Pubitemid 27073791)
37. Enk AH, Jonuleit H, Saloga J, et al. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997;73:309-316. (Pubitemid 27508890)
38. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170:101-110.
39. Gabrilovich DI, Corak J, Ciernik IF, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-490. (Pubitemid 27158075)
40. LaCasce AS, Freedman AS. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. Semin Hematol 2008;45:85-89. (Pubitemid 351434410)
41. Bekisz J, Baron S, Balinsky C, et al. Antiproliferative properties of type I and type II interferon. Pharmaceuticals 2010;3:994-1015.
42. Baldo P, Rupolo M, Compagnoni A, et al. Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev 2010;(1):CD004629.
43. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. J Clin Oncol 1998;16:2825-2833. (Pubitemid 28363048)
44. Ganguly S, Patel V. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2009;2:14.
45. Friedberg JW, Kelly JL, Neuberg D, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009;146:282-291.
46. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161-167.
47. Rothenfusser S, Hornung V, Ayyoub M, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide- specific primary and memory CD8+ T-cell responses in vitro. Blood 2004;103:2162-2169. (Pubitemid 38326234)
48. Harjunpaa A, Taskinen M, Nykter M, et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006; 135:33-42. (Pubitemid 44339457)
49. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-5059. (Pubitemid 46631409)